Pharming Group N.V.

OVERVALUEDPHGUF · OTC · Healthcare
PHGUF·OTC·Healthcare
OVERVALUED
Pharming Group N.V.
18.3%downside
MARKET PRICE
$1.75
FAIR PRICE
$1.43
MARGIN
$0.32
UNDERVALUEDFAIROVERVALUED
P/E RATIO
650.9x
DIV. YIELD
N/A
ROE
0.9%
MARKET CAP
$1B
FPI
fairpriceindex.com

FAIR PRICE VALUATION

18.3%downside

Updated daily

Model: DCF 50% · Relative 30% · Consensus 20%

MARKET PRICE

$1.75

FAIR PRICE

$1.43

MARGIN

$0.32

UNDERVALUEDFAIROVERVALUED

P/E Ratio

650.9x

What is P/E? →

Div. Yield

N/A

ROE

0.9%

Average

Market Cap

$1B

Small-cap

NOW AVAILABLE

Get notified when PHGUF's fair price changes

Push notifications when PHGUF's valuation shifts. Available on iOS and Android.

Download on the App StoreGet it on Google Play

FPI RATING

3.3/ 10

Low debt levels, but limited growth momentum and expensive valuation relative to fundamentals.

Analytical data, not an investment recommendation. Updated daily.

How we calculate this ↗

MARGIN OF SAFETY

A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.

$1.14CONSERVATIVE ENTRY
$1.43FAIR PRICE
$1.75MARKET PRICE

SAFETY MARGIN

20%

Below fair value

ENTRY LEVEL

$1.14

Fair price × 0.80

DISTANCE

34.6%

Price to entry level

At the current price of $1.75, PHGUF trades 34.6% above the conservative entry level of $1.14. This entry level represents a 20% margin of safety below the calculated fair price of $1.43 — a buffer that accounts for estimation uncertainty in the valuation model.

Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗

VALUATION HISTORY

Loading chart data...

P/E RATIO HISTORY

Loading chart data...

METHODOLOGY

How we calculate PHGUF's fair price

Pharming Group N.V.'s fair price of $1.43 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $1.75, PHGUF trades 18.3% above its calculated fair value.

DCF MODEL · 50%

Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting PHGUF's risk profile.

RELATIVE · 30%

Comparing PHGUF's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.

ANALYST · 20%

Aggregated analyst price targets for PHGUF, weighted by recency and analyst accuracy.

TRY IT YOURSELF

Want to test your own assumptions? Use our free calculators to estimate PHGUF's fair value with your own inputs.

LEARN MORE

Bulios

POWERED BY BULIOS

Get full analysis, financials, and AI insights for PHGUF.

Explore on Bulios

FAQ

What is the fair price of PHGUF?+

Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Pharming Group N.V. is $1.43. At the current market price of $1.75, PHGUF trades 18.3% above its calculated fair value.

Is PHGUF overvalued or undervalued?+

Pharming Group N.V. is currently overvalued based on our valuation model. The stock trades at $1.75, which is 18.3% above the fair price of $1.43. The P/E ratio of 650.9x is a key metric in the valuation.

What is the margin of safety for PHGUF?+

With a 20% margin of safety applied to the fair price of $1.43, the conservative entry level for PHGUF is $1.14. At the current market price of $1.75, the stock trades 34.6% above this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.

How often is PHGUF's fair price updated?+

We update fair price calculations for PHGUF daily after market close. The current fair price of $1.43 incorporates the latest market data and sector multiples.

What factors affect PHGUF's fair price calculation?+

PHGUF's fair price of $1.43 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight). Key metrics include P/E of 650.9x, ROE of 0.9%.

Is PHGUF a good buy right now?+

At $1.75, PHGUF trades 18.3% above our fair value estimate of $1.43. The stock is currently overvalued. ROE stands at 0.9% (average). Fair Price Index provides valuation data — always do your own research before investing.

Does PHGUF pay dividends?+

PHGUF does not currently pay a dividend.

RELATED STOCKS

Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.